IN MID- SEPTEMBER the U.S. Food and Drug Administration received a 19-page document with some startling claims about a popular medicine. The online pharmacy Valisure, which tests prescription drugs before dispensing them, said it had found extremely high levels of a probable human carcinogen in the antacid ranitidine, best known under the brand name Zantac. Millions of people around the world use ranitidine; it’s available both with a prescription and over the counter. As for the carcinogen, NDMA, the FDA knew it well: For more than a year the agency had been recalling batches of the blood pressure medication valsartan because they were contaminated with it.
The FDA issued an alert, one that seemed to downplay Valisure’s findings. The agency said it had learned that some ranitidine medicines contained low levels of NDMA, but it wasn’t advising people to stop taking the drug. Those with prescriptions could contact their doctors—if they were worried— and everyone else could consider alternatives on drugstore shelves. In fact, Valisure had found high levels of NDMA in every version of ranitidine it tested and concluded the problem was inherent to the molecule itself. In other words, if Valisure is correct, there is no safe version of ranitidine.
This story is from the December 16, 2019 edition of Bloomberg Businessweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 16, 2019 edition of Bloomberg Businessweek.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
Brazil Yanks the Welcome Mat for Oil Investors
Foreign oil majors have filed an injunction to halt a new tax on crude exports
POINT OF FAILURE
Silicon Valley Bank's collapse exposed a weakness in tech and in the broader economy
Glencore Stays the Course With Coal
The commodities giant’s CEO says the fossil fuel is still necessary, even as he pursues minerals needed for the energy transition
Under Pressure
History shows that when the Federal Reserve is raising rates, an unexpected shock can trigger a recession
Where the Ax Will Fall Next
Another week, another round of job cuts—this time Meta Platforms Inc. is adding to the 11,000 people it fired in November with thousands more, Bloomberg News has reported.
The Case for Ditching Your Wallet
Bellroy's clever phone carrier keeps those last crucial cards close.